Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia
John F Seymour, Hartmut Doehner, Mark D Minden, Richard Stone, Dominique Gambini, Donna Dougherty, CL Beach, Jerry Weaver, Herve Dombret
Leukemia & Lymphoma | TAYLOR & FRANCIS LTD | Published : 2017
All authors equally contributed to, revised, and approved manuscript content, and gave approval for submission to the journal. The authors received editorial support during manuscript development from Sheila Truten and Kelly Dittmore of MC2 Inc., Wynnewood, PA, who were funded by Celgene Corporation. The authors are fully responsible for all content and editorial decisions.